

8<sup>th</sup> May 2020

(1) BSE Ltd  
Listing Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

(2) National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> floor,  
Plot no. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051

**Scrip Code: 500087**

**Scrip Code: CIPLA EQ**

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG  
Societe Anonyme  
35A Boulevard Joseph II,  
L-1840 Luxembourg

Dear Sir / Madam,

**Sub: Receipt of Establishment Inspection Report**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that following the inspection by the United States Food and Drug Administration (USFDA) at our API manufacturing facility in Bommasandra, Bangalore from January 20, 2020 to January 24, 2020, the Company has received the Establishment Inspection Report (EIR), indicating closure of the inspection.

Kindly take the above information on record.

Thanking you,

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Juzer Masta